zanubrutinib
E890926
Bruton tyrosine kinase inhibitor
anticancer drug
orally administered drug
protein kinase inhibitor
small-molecule drug
Zanubrutinib is a small-molecule Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
Bruton tyrosine kinase inhibitor
ⓘ
anticancer drug ⓘ orally administered drug ⓘ protein kinase inhibitor ⓘ small-molecule drug ⓘ |
| approvalYearInUS | 2019 ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
Therapeutic Goods Administration NERFINISHED ⓘ U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToClass | second-generation BTK inhibitors ⓘ |
| boxedWarning | none as of 2024 ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
neutropenia ⓘ rash ⓘ thrombocytopenia ⓘ upper respiratory tract infection ⓘ |
| contraindication | known hypersensitivity to zanubrutinib ⓘ |
| developedBy | BeiGene NERFINISHED ⓘ |
| dosageForm |
oral capsule
ⓘ
oral tablet ⓘ |
| drugInteraction |
strong CYP3A inducers
ⓘ
strong CYP3A inhibitors ⓘ |
| eliminationRoute |
feces
ⓘ
urine ⓘ |
| hasATCCode | L01EL02 ⓘ |
| hasCASNumber | 1691240-69-7 ⓘ |
| hasChEMBLID | CHEMBL3403544 ⓘ |
| hasDrugBankID | DB15035 ⓘ |
| hasHalfLife | approximately 2 to 4 hours ⓘ |
| hasIUPACName | (3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-(1H-pyrazol-4-yl)azetidin-3-ol ⓘ |
| hasPubChemCID | 71226668 ⓘ |
| hasTradeName | Brukinsa NERFINISHED ⓘ |
| hasUNIID | 9JX8XQ24NU ⓘ |
| indication |
Waldenström macroglobulinemia
NERFINISHED
ⓘ
chronic lymphocytic leukemia NERFINISHED ⓘ mantle cell lymphoma ⓘ marginal zone lymphoma ⓘ relapsed or refractory chronic lymphocytic leukemia ⓘ relapsed or refractory mantle cell lymphoma ⓘ small lymphocytic lymphoma NERFINISHED ⓘ |
| mechanismOfAction | covalent inhibition of Bruton tyrosine kinase ⓘ |
| metabolizedBy | CYP3A NERFINISHED ⓘ |
| pregnancyCategory | may cause fetal harm ⓘ |
| proteinBinding | high ⓘ |
| routeOfAdministration | oral ⓘ |
| selectivity | highly selective for BTK compared with first-generation inhibitors ⓘ |
| seriousAdverseEffect |
atrial fibrillation
ⓘ
hemorrhage ⓘ infections ⓘ |
| targets | Bruton tyrosine kinase NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.